Allogene therapeutics, inc. (ALLO)
Income statement / Yearly
Dec'19Dec'18
Operating expenses:
Research and development

144,535

151,860

General and administrative

57,473

40,982

Total operating expenses

202,008

192,842

Loss from operations

-202,008

-192,842

Other income (expense), net:
Change in fair value of convertible note payable

0

21,211

Interest expense

0

3,358

Interest and other income, net

17,351

5,789

Other expenses

268

0

Total other income (expense), net

17,083

-18,780

Loss before income taxes

-184,925

-211,622

Benefit from income taxes

-331

-117

Net loss

-184,594

-211,505

Other comprehensive income:
Net unrealized gain on available-for-sale investments

839

306

Net comprehensive loss

-183,755

-211,199

Net loss per share, basic and diluted (in dollars per share)

-1.83

-7.31

Weighted-average number of shares used in computing net loss per share, basic and diluted (in shares)

101,061

28,948